JP2021520201A5 - - Google Patents

Info

Publication number
JP2021520201A5
JP2021520201A5 JP2020554172A JP2020554172A JP2021520201A5 JP 2021520201 A5 JP2021520201 A5 JP 2021520201A5 JP 2020554172 A JP2020554172 A JP 2020554172A JP 2020554172 A JP2020554172 A JP 2020554172A JP 2021520201 A5 JP2021520201 A5 JP 2021520201A5
Authority
JP
Japan
Prior art keywords
approximately
cancer
antibody
less
antigen
Prior art date
Application number
JP2020554172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520201A (ja
JP7680208B2 (ja
JPWO2019195452A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/025623 external-priority patent/WO2019195452A1/en
Publication of JP2021520201A publication Critical patent/JP2021520201A/ja
Publication of JP2021520201A5 publication Critical patent/JP2021520201A5/ja
Publication of JPWO2019195452A5 publication Critical patent/JPWO2019195452A5/ja
Application granted granted Critical
Publication of JP7680208B2 publication Critical patent/JP7680208B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020554172A 2018-04-04 2019-04-03 抗cd27抗体およびその使用 Active JP7680208B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652790P 2018-04-04 2018-04-04
US62/652,790 2018-04-04
PCT/US2019/025623 WO2019195452A1 (en) 2018-04-04 2019-04-03 Anti-cd27 antibodies and uses thereof

Publications (4)

Publication Number Publication Date
JP2021520201A JP2021520201A (ja) 2021-08-19
JP2021520201A5 true JP2021520201A5 (https=) 2022-04-12
JPWO2019195452A5 JPWO2019195452A5 (https=) 2022-04-12
JP7680208B2 JP7680208B2 (ja) 2025-05-20

Family

ID=66175569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020554172A Active JP7680208B2 (ja) 2018-04-04 2019-04-03 抗cd27抗体およびその使用

Country Status (6)

Country Link
US (1) US12110337B2 (https=)
EP (1) EP3774903A1 (https=)
JP (1) JP7680208B2 (https=)
KR (1) KR20200140315A (https=)
CN (1) CN112292399A (https=)
WO (1) WO2019195452A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
US20230242624A1 (en) 2020-06-02 2023-08-03 Neurimmune Ag HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
WO2022023379A1 (en) * 2020-07-28 2022-02-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for preventing and treating a cancer
CN112194723B (zh) * 2020-09-25 2021-09-21 广州百吉生物制药有限公司 一种免疫细胞在治疗癌症中应用
KR20240051280A (ko) 2021-09-06 2024-04-19 젠맵 에이/에스 Cd27과 결합할 수 있는 항체, 그의 변이체 및 그의 용도
PE20251671A1 (es) 2022-03-15 2025-06-30 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer
TW202413412A (zh) 2022-05-12 2024-04-01 丹麥商珍美寶股份有限公司 在組合療法中能夠結合到cd27之結合劑
WO2023218051A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Il—18bp拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
ES2532399T3 (es) 2003-03-05 2015-03-26 Halozyme, Inc. Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
EP3165540A1 (en) * 2010-04-13 2017-05-10 Celldex Therapeutics, Inc. Antibodies that bind human cd27 and uses thereof
AU2011275749C1 (en) * 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 B7-h1 및 pd-1과 결합하는 항체 및 다른 분자들
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
WO2013138586A1 (en) * 2012-03-15 2013-09-19 Janssen Biotech, Inc. Human anti-cd27 antibodies, methods and uses
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
HK1204557A1 (en) 2012-05-31 2015-11-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-l1
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−1(pd−1)に対する抗体
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
MY189836A (en) * 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
EP3916017A1 (en) 2014-12-22 2021-12-01 PD-1 Acquisition Group, LLC Anti-pd-1 antibodies
US20180044429A1 (en) * 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
TN2017000440A1 (en) * 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
KR102055396B1 (ko) 2015-08-11 2019-12-12 우시 바이올로직스 (케이만) 인코포레이티드 신규한 항-pd-1 항체
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
MX2018007295A (es) 2016-01-11 2019-03-28 Armo Biosciences Inc Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos.
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
JOP20190055A1 (ar) * 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27

Similar Documents

Publication Publication Date Title
JP2021520201A5 (https=)
US11103579B2 (en) Combination of DR5 agonist and anti-PD-1 antagonist and methods of use
JPWO2021194942A5 (https=)
JP2020501531A5 (https=)
JP2021527431A5 (https=)
RU2019138337A (ru) Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии
JP2020103301A5 (https=)
JP2020522495A (ja) 抗lag−3抗体、pd−1経路阻害剤および免疫療法剤の組み合わせを含む組成物
JP2019536470A5 (https=)
JP2018516969A5 (https=)
JP2020510422A5 (https=)
JP2019500892A5 (https=)
JP2018518540A (ja) 新規pd−1免疫調節剤
JP7680208B2 (ja) 抗cd27抗体およびその使用
JP2017535257A5 (https=)
RU2017118225A (ru) Антитела к PD-1 и способы их применения
JPWO2019246514A5 (https=)
JP2012504401A (ja) 抗cxcr4抗体および癌治療のためのそれらの使用
JPWO2019226973A5 (https=)
JP7392145B2 (ja) 免疫療法のためのt細胞二重特異性抗体の作製における最適化された抗cd3アーム
JPWO2021222544A5 (https=)
JPWO2019195452A5 (https=)
JPWO2020076799A5 (https=)
JPWO2022061098A5 (https=)
AU2019306113B2 (en) Anti-human PD-L1 antibodies and their uses